
ELZA OCT and Air Puff tonometry AI paper on cover of the JRS
Can combining corneal OCT and air puff tonometry help better diagnose the earliest stages of keratoconus? That was the question ELZA researcher, Dr. Nanji Lu,

Can combining corneal OCT and air puff tonometry help better diagnose the earliest stages of keratoconus? That was the question ELZA researcher, Dr. Nanji Lu,

The Brazilian Association of Cataract and Refractive Surgery (BRASCRS) awarded the ELZA Institute’s Dr. Emilio Torres-Netto the José Ignacio Barraquer Medal, in recognition of his

Dr. Emilio Torres-Netto, MD, PhD, is a cornea and cataract surgeon at the ELZA Institute in Zurich. Emilio was featured in this month’s issue of

Our latest review on “CXL in thin corneas”. It describes all current approaches how to treat thin keratoconus corneas using corneal cross-linking, including our original approach of swelling the cornea and our latest approach, the sub400 protocol.

Photoactivated chromophore for keratitis-corneal cross-linking (PACK-CXL) has progressed a great deal since it was first developed (1) as a treatment for infectious keratitis and corneal

Ophthalmology times asked Farhad Hafezi about what he thinks are the Ophthalmic Challenges in 2022

Dr. Sebastian Siebelman from the media outlet, “Digital Ophthalmology” interviews ELZA AG’s Chief Executive Officer, Nikki Hafezi, as part of their “Visionaries” series. Several topics

Today, a landmark PACK-CXL trial was published that shows that PACK-CXL is an effective corneal infection therapy.

Prof. Hafezi, Medical Director of the ELZA Institute in Dietikon, Zurich, Switzerland, co-authored a recently published paper that indicated that obese adults have a lower

TouchOphthalmology interviewed Prof. Farhad Hafezi on why it’s taken until now to have an effective epi-on CXL solution.
Stay informed & get the newsletter
You have successfully joined our subscriber list.
Newsletter abonnieren & informiert bleiben
Sie haben sich erfolgreich in unsere Abonnentenliste eingetragen.
Bitte bestätigen Sie Ihr Abonnement, indem Sie auf den Link in der E-Mail klicken, die wir Ihnen gerade geschickt haben.